Ad
AMGN Stock - Amgen Stock Trading
About | Amgen Inc. (NASDAQ:AMGN)
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Quote | Amgen Inc. (NASDAQ:AMGN)
| Last: | $277.63 |
|---|---|
| Change Percent: | -0.21% |
| Open: | $273.16 |
| Close: | $277.63 |
| High: | $280 |
| Low: | $272.28 |
| Volume: | 3,150,773 |
| Last Trade Date Time: | 12/09/2024 03:00:00 am |
News | Amgen Inc. (NASDAQ:AMGN)
-
2024-12-09 04:36:00 ET Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals. Once companies commit to sharing a portion of their profits with...
-
2024-12-07 10:39:00 ET It's time to take a look at the " Dogs of the Dow ." Are the highest-yielding stocks of the Dow Jones Industrial Average (DJINDICES: ^DJI) index undervalued, fantastic buys -- or did their prices fall and dividend yields soar for scary reasons? Stock ...
Message Board Posts | Amgen Inc. (NASDAQ:AMGN)
| Subject | By | Source | When |
|---|---|---|---|
| AMGEN INC is having a great day! | MiamiGent | investorshub | 11/08/2022 5:04:41 PM |
| whytestocks: $AMGN News Article - Why Amgen Is Up More Than 6% Today | whytestocks | investorshangout | 10/11/2022 6:45:49 PM |
| whytestocks: $AMGN News Article - AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS RE | whytestocks | investorshangout | 02/08/2022 4:25:52 PM |
| WAS SUPPOSED TO BE BIG IN pm | ernie44 | investorshub | 02/04/2022 2:30:34 PM |
| I was reading on another board where someone | all the way up green | investorshub | 01/05/2022 4:44:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
2024-12-09 04:36:00 ET Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals. Once companies commit to sharing a portion of their profits with...
-
2024-12-07 10:39:00 ET It's time to take a look at the " Dogs of the Dow ." Are the highest-yielding stocks of the Dow Jones Industrial Average (DJINDICES: ^DJI) index undervalued, fantastic buys -- or did their prices fall and dividend yields soar for scary reasons? Stock ...
-
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PR Newswire Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% ...